Treatments for Brain Metastases With Poor Prognostic Factors

• Conditions: Brain Metastases

• Registration Number: NCT05609162
• Lead Sponsor: Sun Yat-sen University

Brief Summary

The goal of this observational study is to learn about treatments in brain metastases with poor prognostic factors. The main questions it aims to answer are:

* What kind of local treatment provides a survival benefit for patients with poor prognostic factors?

* What kind of systemic treatment provides a survival benefit for patients with poor prognostic factors?

* Will the combination of local treatment and systemic treatment provide a survival benefit for patients with poor prognostic factors?

Participants will be asked to provide personal information about their living status, symptoms, and disease control during the follow-up.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2022-11-02
• Study First Submitted QC: 2022-11-04
• Study First Posted: 2022-11-08
• Status Verified: 2022-12
• Last Update Submitted: 2022-12-13
• Study Start: 2022-12-15
• Last Update Posted: 2022-12-15
• Primary Completion: 2023-11-20
• Study Completion: 2024-11-20

Recruitment & Eligibility

• Status: ENROLLING_BY_INVITATION
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

1. Evidence of pathological diagnosis of primary tumor;
2. Brain metastases confirmed by enhanced magnetic resonance imaging;
3. Complete clinical information

Exclusion Criteria

1. Survival time less than 30 days;
2. If surgical treatment is accepted, the surgical treatment is not tumor resection, but ventricle puncture, biopsy and other non-tumor reducing surgery;
3. Incomplete clinical data;
4. Patients with 2 or more types of tumors.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
OS	From date of first follow-up until the date of documented death from any cause, assessed up to 120 months	Overall survival time

Secondary Outcome Measures

Name	Time	Method
PFS	From date of first follow-up until the date of first documented progression, assessed up to 120 months	Progression-free survival time

Trial Locations

Locations (1)

Sun Yat-sen University Cancer Center; 🇨🇳 Guangzhou, Guangdong, China